Strand Therapuetics, BeiGene to develop mRNA platform tech
January 11, 2021 -- Strand Therapeutics and BeiGene have entered into an option and license agreement in order to develop and commercialize Strand's messenger RNA (mRNA) treatments for solid tumors. Strand's platform is designed to deliver mRNA directly to a tumor site in order to modify the tumor microenvironment. The platform has the potential to use programmable, long-acting mRNA to treat deadly diseases, including solid tumor cancers. Under the agreement, BeiGene has secured the option to an exclusive license that would allow the firm to develop and commercialize in Australia, New Zealand...